article thumbnail

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

In clinical trials, the highest dose was set at 960 mg; whilst judged to be well-tolerated, 45 percent of patients receiving this dose showed serious complications and 7 percent had to stop treatment. Petra holds a D.Phil in synthetic organic chemistry and am MBA from Imperial College London.

article thumbnail

Women in STEM with Dr Petra Dieterich

Drug Target Review

Working in the CRO and CDMO environment she has led projects for customers across the globe, helping them to achieve their goals in clinical trials and low-volume commercial manufacture. Petra holds a D.Phil in synthetic organic chemistry and an MBA from Imperial College London.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Welcome to new Director David Hulcoop

The Open Targets Blog

After completing my PhD in organic chemistry at the University of Cambridge, I went to Canada as a Leverhulme Trust postdoctoral fellow. These very large teams need to stay on track to hit delivery milestones for clinical trials. Photo credit: Jeff Dowling, EMBL-EBI What is your professional background?

article thumbnail

Marquis Who’s Who Honors David R. Elmaleh, PhD, with Inclusion in Who’s Who in the World

The Pharma Data

A graduate of the Hebrew University of Jerusalem, he earned a Bachelor of Science in chemistry and physics and a Master of Science in physical organic chemistry before completing a Doctor of Philosophy in 1971. and Pure Tech Health. He also remains active as the chief executive officer and chairperson of AZTherapies Inc.

article thumbnail

Unlocking the potential of antibody drug conjugates

Drug Target Review

At Zymeworks we apply a holistic approach to optimise each of the ADC components, leveraging insights gained from clinical trials and real-world clinical experience to inform the design of novel ADCs. He has more than 17 years of experience in ADC and protein chemistry research and drug development.

Drugs 69
article thumbnail

How to Get Drugs Into the Brain

Drug Hunter

Overall, only a few prodrugs for CNS disorders have even reached clinical trials , so for the most part traditional property-based drug design remains the best bet for the vast majority of programs. What is K p,uu ? Recently, Dennis helped advance programs on Chagas disease and Malaria as a project team leader.

Drugs 206
article thumbnail

Women in Stem with Dr Rachel Lagiakos

Drug Target Review

Coupling my desire to be a scientist with my keen sense of adventure, I moved to Alaska out of high school to begin my undergraduate studies in chemistry, applying myself to my STEM classes whilst also climbing mountains and chasing Northern Lights.